EVONIK DEGUSSA GMBH

EVONIK DEGUSSA GMBH has been granted 686 US utility patents between 2015 and 2021, placing EVONIK DEGUSSA GMBH at rank #653 across all assignees tracked by PlainPatent. This portfolio spans 125 distinct Cooperative Patent Classification (CPC) subclasses, averaging 15.6 claims per patent with primary concentration in C07C (ACYCLIC OR CARBOCYCLIC COMPOUNDS). As a Foreign Corporation, EVONIK DEGUSSA GMBH is one of the broader-portfolio assignees in the PatentsView dataset. The composite Innovation Score of 56.9/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Filing cadence tells the strategic story. Between 2020 and 2025 the company received 23 grants, compared with 663 in the 2015–2019 window — a -97% shift in five-year velocity. A cooling filing rate may reflect portfolio consolidation, shifting priorities, or reduced R&D throughput. The Foreign Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.

Claim depth and technology breadth together indicate competitive posture. EVONIK DEGUSSA GMBH's 15.6 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while a diversified footprint across 100+ CPC subclasses spreads risk across many technology fronts. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark EVONIK DEGUSSA GMBH against peers pursuing similar technology classes.